Cargando…

Prognostic significance of AP-2α/γ targets as cancer therapeutics

Identifying genes with prognostic importance could improve cancer treatment. An increasing number of reports suggest the existence of successful strategies based on seemingly “untargetable” transcription factors. In addition to embryogenesis, AP-2 transcription factors are known to play crucial role...

Descripción completa

Detalles Bibliográficos
Autores principales: Kołat, Damian, Kałuzińska, Żaneta, Bednarek, Andrzej K., Płuciennik, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971500/
https://www.ncbi.nlm.nih.gov/pubmed/35361846
http://dx.doi.org/10.1038/s41598-022-09494-1
_version_ 1784679646849138688
author Kołat, Damian
Kałuzińska, Żaneta
Bednarek, Andrzej K.
Płuciennik, Elżbieta
author_facet Kołat, Damian
Kałuzińska, Żaneta
Bednarek, Andrzej K.
Płuciennik, Elżbieta
author_sort Kołat, Damian
collection PubMed
description Identifying genes with prognostic importance could improve cancer treatment. An increasing number of reports suggest the existence of successful strategies based on seemingly “untargetable” transcription factors. In addition to embryogenesis, AP-2 transcription factors are known to play crucial roles in cancer development. Members of this family can be used as prognostic factors in oncological patients, and AP-2α/γ transcription factors were previously investigated in our pan-cancer comparative study using their target genes. The present study investigates tumors that were previously found similar with an emphasis on the possible role of AP-2 factors in specific cancer types. The RData workspace was loaded back to R environment and 3D trajectories were built via Monocle3. The genes that met the requirement of specificity were listed using top_markers(), separately for mutual and unique targets. Furthermore, the candidate genes had to meet the following requirements: correlation with AP-2 factor (through Correlation AnalyzeR) and validated prognostic importance (using GEPIA2 and subsequently KM-plotter or LOGpc). Eventually, the ROC analysis was applied to confirm their predictive value; co-dependence of expression was visualized via BoxPlotR. Some similar tumors were differentiated by AP-2α/γ targets with prognostic value. Requirements were met by only fifteen genes (EMX2, COL7A1, GRIA1, KRT1, KRT14, SLC12A5, SEZ6L, PTPRN, SCG5, DPP6, NTSR1, ARX, COL4A3, PPEF1 and TMEM59L); of these, the last four were excluded based on ROC curves. All the above genes were confronted with the literature, with an emphasis on the possible role played by AP-2 factors in specific cancers. Following ROC analysis, the genes were verified using immunohistochemistry data and progression-related signatures. Staining differences were observed, as well as co-dependence on the expression of e.g. CTNNB1, ERBB2, KRAS, SMAD4, EGFR or MKI67. In conclusion, prognostic value of targets suggested AP-2α/γ as candidates for novel cancer treatment. It was also revealed that AP-2 targets are related to tumor progression and that some mutual target genes could be inversely regulated.
format Online
Article
Text
id pubmed-8971500
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89715002022-04-05 Prognostic significance of AP-2α/γ targets as cancer therapeutics Kołat, Damian Kałuzińska, Żaneta Bednarek, Andrzej K. Płuciennik, Elżbieta Sci Rep Article Identifying genes with prognostic importance could improve cancer treatment. An increasing number of reports suggest the existence of successful strategies based on seemingly “untargetable” transcription factors. In addition to embryogenesis, AP-2 transcription factors are known to play crucial roles in cancer development. Members of this family can be used as prognostic factors in oncological patients, and AP-2α/γ transcription factors were previously investigated in our pan-cancer comparative study using their target genes. The present study investigates tumors that were previously found similar with an emphasis on the possible role of AP-2 factors in specific cancer types. The RData workspace was loaded back to R environment and 3D trajectories were built via Monocle3. The genes that met the requirement of specificity were listed using top_markers(), separately for mutual and unique targets. Furthermore, the candidate genes had to meet the following requirements: correlation with AP-2 factor (through Correlation AnalyzeR) and validated prognostic importance (using GEPIA2 and subsequently KM-plotter or LOGpc). Eventually, the ROC analysis was applied to confirm their predictive value; co-dependence of expression was visualized via BoxPlotR. Some similar tumors were differentiated by AP-2α/γ targets with prognostic value. Requirements were met by only fifteen genes (EMX2, COL7A1, GRIA1, KRT1, KRT14, SLC12A5, SEZ6L, PTPRN, SCG5, DPP6, NTSR1, ARX, COL4A3, PPEF1 and TMEM59L); of these, the last four were excluded based on ROC curves. All the above genes were confronted with the literature, with an emphasis on the possible role played by AP-2 factors in specific cancers. Following ROC analysis, the genes were verified using immunohistochemistry data and progression-related signatures. Staining differences were observed, as well as co-dependence on the expression of e.g. CTNNB1, ERBB2, KRAS, SMAD4, EGFR or MKI67. In conclusion, prognostic value of targets suggested AP-2α/γ as candidates for novel cancer treatment. It was also revealed that AP-2 targets are related to tumor progression and that some mutual target genes could be inversely regulated. Nature Publishing Group UK 2022-03-31 /pmc/articles/PMC8971500/ /pubmed/35361846 http://dx.doi.org/10.1038/s41598-022-09494-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kołat, Damian
Kałuzińska, Żaneta
Bednarek, Andrzej K.
Płuciennik, Elżbieta
Prognostic significance of AP-2α/γ targets as cancer therapeutics
title Prognostic significance of AP-2α/γ targets as cancer therapeutics
title_full Prognostic significance of AP-2α/γ targets as cancer therapeutics
title_fullStr Prognostic significance of AP-2α/γ targets as cancer therapeutics
title_full_unstemmed Prognostic significance of AP-2α/γ targets as cancer therapeutics
title_short Prognostic significance of AP-2α/γ targets as cancer therapeutics
title_sort prognostic significance of ap-2α/γ targets as cancer therapeutics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971500/
https://www.ncbi.nlm.nih.gov/pubmed/35361846
http://dx.doi.org/10.1038/s41598-022-09494-1
work_keys_str_mv AT kołatdamian prognosticsignificanceofap2agtargetsascancertherapeutics
AT kałuzinskazaneta prognosticsignificanceofap2agtargetsascancertherapeutics
AT bednarekandrzejk prognosticsignificanceofap2agtargetsascancertherapeutics
AT płuciennikelzbieta prognosticsignificanceofap2agtargetsascancertherapeutics